Table 3.
Characteristics of patients assigned to different guideline adherence subgroups
| Patient characteristicsa | Guideline adherence subgroupsb | ||
|---|---|---|---|
| “Green” level of guideline adherence | “Yellow” level of guideline adherence | “Red” level of guideline adherence | |
| N (%) | 4096 (14.4%) | 21,386 (75.2%) | 2974 (10.5%) |
| With incident IS | 1949 (42.6%) | 2277 (49.8%) | 346 (7.6%) |
| With incident MI | 599 (21.2%) | 2140 (75.8%) | 83 (2.9%) |
| With incident HF | 1982 (11.2%) | 14,609 (82.7%) | 1084 (6.1%) |
| With incident CAD | 1561 (15.2%) | 7898 (76.7%) | 833 (8.1%) |
| Age (years) | 71.9 ± 10.6 | 74.5 ± 10.8 | 75.6 ± 12.1 |
| Female gender | 1945 (47.5%) | 11,724 (54.8%) | 1617 (54.4%) |
| CCI | 4.9 ± 2.2 | 5.2 ± 2.4 | 5.8 ± 2.9 |
| aDCSI | 3.9 ± 1.7 | 3.9 ± 1.9 | 3.6 ± 1.9 |
| Kidney disease | 716 (17.5%) | 5286 (24.7%) | 732 (24.6%) |
| Hypertension | 375 (90.8%) | 1684 (92.1%) | 612 (79.4%) |
Description of patient characteristics according to the level of guideline adherence for recommended drug therapies related to IS, MI, HF and CAD
Values in table are presented as the mean ± SD or as a number with the percentage in parenthesis
a aDCSI and CCI are measures of patients’ comorbidity status; their calculation is based on observed diagnosed comorbidities within the 12 months prior to index (including index date). Frequencies for patients with kidney disease (ICD 10: I12–13, N17–N19 or P96.0) and hypertension (ICD 10: I10–I15) are based on observed diagnoses within 12 months prior to index
bSee Table1 and text for full description of treatment groups